retatrutide phase 2 trial new england journal of medicine Number 1 Top Cardiometabolic Story 2023: with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 π¨ Today, retatrutide, the GIP/GLP-1/glucagon
Pay in 4 interest-free payments of $7.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14



























